Greenland Mines Ltd (NASDAQ: GRML) has announced a series of corporate milestones that mark its transformation into a focused rare earths and critical minerals company. The company revealed plans to spin off its biotechnology division in the fourth quarter of 2026, while simultaneously advancing its mining operations in Greenland. This strategic shift is underscored by Nasdaq's formal approval of the company's application relating to its March 2026 transaction, which resolves prior deficiencies and brings Greenland Mines into full compliance with listing requirements.
The company completed its acquisition of the Sarfartoq project on Sept. 1 following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. This assessment highlights the project's potential to significantly contribute to the global supply of neodymium-praseodymium (NdPr) oxide, a critical component in permanent magnets used in electric vehicles and wind turbines.
Greenland Mines said planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years. This positions the company as a key player in the effort to diversify the rare earth supply chain away from China, which currently dominates the market.
The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project. This governance change is expected to bring additional expertise in capital markets and strategic development as the company pursues its ambitious growth plans.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow Greenland Mines to focus entirely on its mining operations. This separation is designed to unlock value for shareholders by creating two distinct, pure-play companies: one in critical minerals and one in biotechnology.
The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. This approach is part of its broader North Atlantic Critical Metals Corridor vision, which aims to link Greenland resources with allied downstream jurisdictions and industrial infrastructure.
These developments come at a time when global demand for rare earth elements is surging, driven by the transition to clean energy and the proliferation of advanced technologies. Greenland Mines' progress on the Sarfartoq project and its strategic pivot are likely to attract attention from investors seeking exposure to the critical minerals sector.
For more information on the latest news and updates relating to GRML, visit the company's newsroom at https://ibn.fm/GRML.
